With your help, we carry out clinical trials of new or improved treatment for rare pediatric cancers.
Let's end Childhood Cancer
With your help, we carry out clinical trials of new or improved treatment for rare pediatric cancers.
How we help
Rare pediatric cancers, such as Ewing sarcoma and osteosarcoma, do not represent a commercially attractive market for cancer research investment. As a result, potentially effective therapies for childhood cancer often go untested in kids and the standards of care fail to improve. We step in to sponsor early-phase trials, reducing the financial risk for developers and enabling promising therapies for rare cancers to reach children sooner.
Our approach
Our pediatric oncology, GMP, and GCP experts collaborate to develop the most effective clinical development pathway for childhood cancer therapies. We then fund and/or conduct early phase clinical trials that test the safety and efficacy of these new treatments.